rs397517077
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_005188.4(CBL):c.1096-4_1096-1del variant causes a splice acceptor, splice polypyrimidine tract, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
CBL
NM_005188.4 splice_acceptor, splice_polypyrimidine_tract, intron
NM_005188.4 splice_acceptor, splice_polypyrimidine_tract, intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 9.60
Genes affected
CBL (HGNC:1541): (Cbl proto-oncogene) This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.048144065 fraction of the gene. Cryptic splice site detected, with MaxEntScore 4.6, offset of -43, new splice context is: gttaacatttataattgcAGtta. Cryptic site results in frameshift change. If cryptic site found is not functional and variant results in exon loss, it results in inframe change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-119278161-CAAAG-C is Pathogenic according to our data. Variant chr11-119278161-CAAAG-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 45197.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CBL | NM_005188.4 | c.1096-4_1096-1del | splice_acceptor_variant, splice_polypyrimidine_tract_variant, intron_variant | ENST00000264033.6 | NP_005179.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CBL | ENST00000264033.6 | c.1096-4_1096-1del | splice_acceptor_variant, splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_005188.4 | ENSP00000264033 | P2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
RASopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 04, 2022 | For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site results in skipping of exon 8 or part of exon 8, but is expected to preserve the integrity of the reading-frame (PMID: 25952305). ClinVar contains an entry for this variant (Variation ID: 45197). Disruption of this splice site has been observed in individuals with CBL-related conditions (PMID: 25358541, 25952305, 28589114; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a splice site in intron 7 of the CBL gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 14, 2014 | This mutation is denoted c.1096-4_1096-1delAAAG (IVS7-4_IVS7-1delAAAG) at the cDNA level. Using lower case letters to denote intronic sequence and capital letters to denote exonic sequence, the normal sequence with the bases that are deleted in braces is: aatc{aaag}GAAC. The c.1096-4_1096_1delAAAG mutation in intron 7 in the CBL gene (NM_005188.2) has not been reported previously as a disease-causing mutation nor as a benign polymorphism, to our knowledge. This mutation has previously been observed at GeneDx in a patient referred for testing of the comprehensive panel for Noonan syndrome and related disorders. The c.1096-4_1096-1delAAAG mutation was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The c.1096-4_1096-1delAAAG mutation in the CBL gene destroys the splice acceptor site of exon 8, which is an in-frame exon encoding portions of the Zn-finger ring and linker region. The c.1096-4_1096-1delAAAG mutation is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Another splice site mutation that destroys this acceptor site (c.1096-1 G>C) has been reported in a homozygous state in a patient with juvenile myelomonocytic leukemia (JMML), caf? au lait spots, cryptorchidism, juvenile xanthogranuloma, poor growth, and developmental delay (Niemeyer et al., 2010). We interpret c.1096-4_1096-1delAAAG as a disease-causing mutation. The presence of this mutation is consistent with the diagnosis of Noonan syndrome-like disorder. The variant is found in NOONAN panel(s). - |
CBL-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Apr 13, 2017 | - - |
Noonan syndrome Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 08, 2012 | The 1096-4_1096-1del variant in CBL has not been reported in the literature nor previously identified by our laboratory. This deletion removes 4 base pairs incl uding the invariant region (-1/2) of the splice consensus sequence and is predic ted to cause a likely impact on splicing. Importantly, another variant (1096-1G> C) affecting the same splice site has been identified in a patient with clinical features of Noonan syndrome and juvenile myelomonocytic leukemia (Niemeyer 2010 ). Loss of this splice site has been shown to cause skipping of exon 8 or retent ion of intron 7, resulting in proteins that lack essential regions of the linker and ring finger domains (Niemeyer 2010). Loss of CBL function results in Ras hy peractivation, which is associated with Noonan syndrome-like disorder with or wi thout JMML. In summary, the 1096-4-1096-1del variant in CBL is likely to be path ogenic, though additional studies are required to fully establish its pathogenic ity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AL_spliceai
Position offset: 5
Find out detailed SpliceAI scores and Pangolin per-transcript scores at